Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for shares of Entrada Therapeutics in a note issued to investors on Monday, March 31st. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.92) per share for the quarter, down from their prior forecast of ($0.86). HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics' Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($1.12) EPS and FY2025 earnings at ($4.11) EPS.
Entrada Therapeutics Trading Down 5.1 %
Shares of TRDA traded down $0.42 during mid-day trading on Thursday, reaching $7.77. 60,003 shares of the stock traded hands, compared to its average volume of 119,653. The company has a market cap of $292.11 million, a price-to-earnings ratio of 4.88 and a beta of 0.04. Entrada Therapeutics has a 1 year low of $7.42 and a 1 year high of $21.79. The firm has a fifty day moving average price of $11.46 and a 200 day moving average price of $15.17.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The business had revenue of $12.25 million for the quarter, compared to analyst estimates of $11.95 million.
Institutional Trading of Entrada Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. KLP Kapitalforvaltning AS purchased a new stake in Entrada Therapeutics in the fourth quarter valued at approximately $36,000. BNP Paribas Financial Markets purchased a new position in Entrada Therapeutics in the fourth quarter worth $57,000. Virtus ETF Advisers LLC bought a new position in Entrada Therapeutics in the fourth quarter valued at $68,000. AlphaQuest LLC bought a new stake in Entrada Therapeutics during the fourth quarter worth about $70,000. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Entrada Therapeutics by 53,455.6% in the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock worth $83,000 after purchasing an additional 4,811 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company's stock.
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Further Reading
Before you consider Entrada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.
While Entrada Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
